Phys Vivas · haematological
Myeloproliferative Neoplasms — Viva Defence
DCE viva defence for Myeloproliferative Neoplasms.
On this page
Study tools
Target exams
Myeloproliferative Neoplasms Viva
Long Case Viva Defence
Opening statement
"This patient presents with a problem best framed as Myeloproliferative Neoplasms. My priorities are to identify red flags, confirm the mechanism with purposeful investigations, start a sequenced management plan, and integrate multimorbidity and follow-up." [1] [2]
Examiner questions
Q1: "What makes this urgent?" [1]
"I look for threats to airway, perfusion, neurology, metabolism, infection or bleeding, and I escalate those before elective work-up." [1] [2]
Q2: "What is your first investigation package?" [2]
"I order tests that change management now, not a scattergun panel." [1] [2]
Q3: "Walk me through treatment." [1]
"Stabilise, treat the mechanism, prevent complications, and plan monitoring." [1] [2] [3]
Q4: "What is the classic trap?" [2]
"Treating a label without confirming the discriminating mechanism, or delaying escalation." [1] [2]
References3ShowHide
- [1]Tefferi A Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management American journal of hematology, 2023.PMID 36680511
- [2]Tremblay D, Kremyanskaya M, Mascarenhas J et al. Diagnosis and Treatment of Polycythemia Vera: A Review JAMA, 2025.PMID 39556352
- [3]Tefferi A, Gangat N, Loscocco GG et al. Essential Thrombocythemia: A Review JAMA, 2025.PMID 39869325